What the label lists and what reports show
Dichlorphenamide side effects
Dichlorphenamide's FDA label: “Most common adverse reactions (incidence at least 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Xeris Pharmaceuticals, Inc.” FAERS holds 1,639 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is paraesthesia (303 reports).
- Generic listed
Check it at the source: the dichlorphenamide FDA label on DailyMed (effective March 4, 2026, Xeris Pharmaceuticals, Inc.); the FDA FAERS public dashboard.
What does the label list?
From the label: adverse reactionsMost common adverse reactions (incidence at least 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Xeris Pharmaceuticals, Inc.
Table 1: Adverse Reactions in Patients Treated with dichlorphenamide with Incidence ≥ 5% and more common than in Patients Treated with Placebo in Study 1
This table is printed in the Dichlorphenamide label published by Torrent pharmaceuticals limited of March 5, 2026; the label quoted above does not print one.
| Adverse Reaction | Dichlorphenamide N = 36 (%) | Placebo N = 29 (%) |
|---|---|---|
| Paresthesia | 44 | 14 |
| Cognitive disorder 1 | 14 | 7 |
| Dysgeusia | 14 | 0 |
| Headache | 8 | 7 |
| Hypoesthesia | 8 | 0 |
| Lethargy | 8 | 0 |
| Dizziness | 6 | 0 |
| Nausea | 6 | 0 |
| Malaise | 6 | 0 |
| Muscle spasms | 8 | 0 |
| Muscle twitching | 6 | 0 |
| Pharyngolaryngeal pain | 6 | 0 |
| Pruritus | 6 | 0 |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
From the label: adverse reactions, continuedThe following serious adverse reactions are described elsewhere in labeling: Hypersensitivity and Other Life-Threatening Reactions [see Warnings and Precautions (5.1) ] Hypokalemia [see Warnings and Precautions (5.3) ] Metabolic Acidosis [see Warnings and Precautions (5.4) ] Falls [see Warnings and Precautions (5.5) ] Most common adverse reactions (incidence at least 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Xeris Pharmaceuticals, Inc. at 1-855-324-8912, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In a 9-week randomized controlled trial in adults with hyperkalemic or hypokalemic periodic paralysis (Study 1), the most common adverse reactions in patients treated with KEVEYIS, with rates greater than placebo, were paresthesia, cognitive disorder, dysgeusia, and confusional state. The mean dose of KEVEYIS was 94 mg/day in patients with hypokalemic periodic paralysis and 82 mg/day in patients with hyperkalemic periodic paralysis. …
Source: FDA drug label, Xeris Pharmaceuticals, Inc., effective March 4, 2026 (SPL set d30a87b9-90fb-35b2-e053-2995a90aea2c), via openFDA; the full label on DailyMed
What do FAERS reports show?
1,639 reports list dichlorphenamide among the medicines taken, each a report of something that happened, not proof the medicine caused it; 13 are coded as a death and 247 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 22 reactions below, 13 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Dichlorphenamide: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions